KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Total Current Liabilities: 2009-2025

Historic Total Current Liabilities for Acadia Pharmaceuticals (ACAD) over the last 17 years, with Sep 2025 value amounting to $356.6 million.

  • Acadia Pharmaceuticals' Total Current Liabilities rose 3.67% to $356.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $356.6 million, marking a year-over-year increase of 3.67%. This contributed to the annual value of $394.9 million for FY2024, which is 55.31% up from last year.
  • According to the latest figures from Q3 2025, Acadia Pharmaceuticals' Total Current Liabilities is $356.6 million, which was up 8.05% from $330.0 million recorded in Q2 2025.
  • Acadia Pharmaceuticals' Total Current Liabilities' 5-year high stood at $394.9 million during Q4 2024, with a 5-year trough of $88.2 million in Q3 2021.
  • In the last 3 years, Acadia Pharmaceuticals' Total Current Liabilities had a median value of $330.0 million in 2025 and averaged $297.5 million.
  • Its Total Current Liabilities has fluctuated over the past 5 years, first dropped by 9.34% in 2021, then surged by 102.38% in 2023.
  • Quarterly analysis of 5 years shows Acadia Pharmaceuticals' Total Current Liabilities stood at $96.1 million in 2021, then spiked by 30.77% to $125.6 million in 2022, then skyrocketed by 102.38% to $254.3 million in 2023, then spiked by 55.31% to $394.9 million in 2024, then grew by 3.67% to $356.6 million in 2025.
  • Its last three reported values are $356.6 million in Q3 2025, $330.0 million for Q2 2025, and $302.5 million during Q1 2025.